Molecular targeted therapies in metastatic melanoma

References

• National Cancer InstituteA snapshot of melanoma2012 Available from: http://www.cancer.gov/researchandfunding/snapshots/pdf/Melanoma-Snapshots.pdf. Accessed January 16, 2013.
   Google Scholar
• National Cancer InstituteSEER Stats Facts sheets. Melanoma of the skin Available from: http://seer.cancer.gov/statfacts/html/melan.html. Accessed April 16, 2013
   Google Scholar
• EggermontAMSchadendorfDMelanoma and immunotherapyHematol Oncol Clin North Am20092354756419464602
   PubMed Web of Science ®Google Scholar
• EggermontAMKirkwoodJMRe-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?Eur J Cancer2004401825183615288283
   PubMed Web of Science ®Google Scholar
• ChapmanPBEinhornLHMeyersMLPhase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanomaJ Clin Oncol1999172745275110561349
   PubMed Web of Science ®Google Scholar
• MiddletonMRGrobbJJAaronsonNRandomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaJ Clin Oncol20001815816610623706
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol1999172105211610561265
   PubMed Web of Science ®Google Scholar
• TsaoHAtkinsMBSoberAJManagement of cutaneous melanomaN Engl J Med2004351998101215342808
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMacDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med20113642517252621639810
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
   PubMed Web of Science ®Google Scholar
• DeanELoriganPAdvances in the management of melanoma: targeted therapy, immunotherapy and future directionsExpert Rev Anticancer Ther2012121437144823249108
   PubMed Web of Science ®Google Scholar
• MidorikawaYTsujiSTakayamaTAburataniHGenomic approach towards personalized anti-cancer drug therapyPharmacogenomics20121319119922256868
   PubMed Web of Science ®Google Scholar
• AwadaAVandoneAMAftimosPPersonalized management of patients with solid cancers: moving from patient characteristics to tumor biologyCurr Opin Oncol20122429730422410457
   PubMed Web of Science ®Google Scholar
• FinnLMarkovicSNJosephRWTherapy for metastatic melanoma: the past, the present and futureBMC Med2012102322385436
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature200241794995412068308
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med20113642507251621639808
   PubMed Web of Science ®Google Scholar
• GoldsteinAMChanMHarlandMLund Melanoma Study Group, Melanoma Genetics Consortium (GenoMEL)Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsJ Med Genet2007449910616905682
   PubMed Web of Science ®Google Scholar
• MeyerLJZoneJHGenetics of cutaneous melanomaJ Invest Dermatol1994103Suppl 5112S116S7963671
   PubMed Web of Science ®Google Scholar
• SekulicAHaluskaPJrMillerAJMelanoma Study Group of Mayo Clinic Cancer CenterMalignant melanoma in the 21st century: the emerging molecular landscapeMayo Clin Proc20088382584618613999
   PubMed Web of Science ®Google Scholar
• GilchrestBAEllerMSGellerACThe pathogenesis of melanoma induced by ultraviolet radiationN Engl J Med19993401341134810219070
   PubMed Web of Science ®Google Scholar
• GandiniSSeraFCattaruzzaMSMeta-analysis of risk factors for cutaneous melanoma: I. Common and atypical neviEur J Cancer200541284415617989
   PubMed Web of Science ®Google Scholar
• TannousZSMihmMCJrSoberAJDuncanLMCongenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical managementJ Am Acad Dermatol20055219720315692463
   PubMed Web of Science ®Google Scholar
• WattAJKotsisSVChungKCRisk of melanoma arising in large congenital melanocytic nevi: a systematic reviewPlast Reconstr Surg20041131968197415253185
   PubMed Web of Science ®Google Scholar
• BishopDTDemenaisFGoldsteinAMMelanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanomaJ Natl Cancer Inst20029489490312072543
   PubMed Web of Science ®Google Scholar
• BeggCBOrlowIHummerAJGenes Environment and Melanoma Study GroupLifetime risk of melanoma in CDKN2A mutation carriers in a population-based sampleJ Natl Cancer Inst2005971507151516234564
   PubMed Web of Science ®Google Scholar
• AbdullahCWangXBeckerDExpression analysis and molecular targeting of cyclin-dependent kinases in advanced melanomaCell Cycle20111097798821358262
   PubMed Web of Science ®Google Scholar
• MannMBKaldisPCell cycle transitions and Cdk inhibition in melanoma therapy: cyclin’ through the optionsCell Cycle201110134921464616
   PubMed Web of Science ®Google Scholar
• BennettDCHow to make a melanoma: what do we know of the primary clonal events?Pigment Cell Melanoma Res200821273818353141
   PubMed Web of Science ®Google Scholar
• PetitjeanAMatheEKatoSImpact of mutant p53functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHum Mutat20072862262917311302
   PubMed Web of Science ®Google Scholar
• KamijoTWeberJDZambettiGZindyFRousselMFSherrCJFunctional and physical interactions of the ARF tumor suppressor with p53 and Mdm2Proc Natl Acad Sci U S A199895829282979653180
   PubMed Web of Science ®Google Scholar
• ShangarySWangSTargeting the MDM-p53 interaction for cancer therapyClin Cancer Res2008145318532418765522
   PubMed Web of Science ®Google Scholar
• NikolaouVAStratigosAJFlahertyKTTsaoHMelanoma: new insights and new therapiesJ Invest Dermatol201213285486322217739
   PubMed Web of Science ®Google Scholar
• Al-MullaFMacKenzieEMDifferences in in vitro invasive capacity induced by differences in Ki-Ras protein mutationsJ Pathol200119554955611745690
   PubMed Web of Science ®Google Scholar
• FecherLAAmaravadiRKFlahertyKTThe MAPK pathway in melanomaCurr Opin Oncol20082018318918300768
   PubMed Web of Science ®Google Scholar
• DownwardJTargeting RAS signaling pathways in cancer therapyNat Rev Cancer20033112212509763
   PubMed Web of Science ®Google Scholar
• HoubenRBeckerJCKappelAConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisJ Carcinog20043615046639
   PubMedGoogle Scholar
• PlatzAEgyhaziSRingborgUHanssonJHuman cutaneous melanoma: a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMol Oncol2008139540519383313
   PubMed Web of Science ®Google Scholar
• SclafaniFGulloGSheahanKBRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumor phenotypes and clinical implicationsCrit Rev Oncol Hematol12112012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• LongGVMenziesAMNagrialAMPrognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol2011291239124621343559
   PubMed Web of Science ®Google Scholar
• DumazNHaywardRMartinJIn melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingCancer Res2006669483949117018604
   PubMed Web of Science ®Google Scholar
• MooiWJPeeperDSOncogene-induced cell senescence – halting on the road to cancerN Engl J Med20063551037104616957149
   PubMed Web of Science ®Google Scholar
• FedorenkoIVGibneyGTSmalleyKSNRAS mutant melanoma: biological behavior and future strategies for therapeutic managementOncogene10152012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• DevittBLiuWSalemiRClinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell Melanoma Res20112466667221615881
   PubMed Web of Science ®Google Scholar
• JakobJABassettRLJrNgCSNRAS mutation status is an independent prognostic factor in metastatic melanomaCancer20121184014402322180178
   PubMed Web of Science ®Google Scholar
• EllerhorstJAGreeneVREkmekciogluSClinical correlates of NRAS and BRAF mutations in primary human melanomaClin Cancer Res20111722923520975100
   PubMed Web of Science ®Google Scholar
• MarquetteAAndréJBagotMBensussanADumazNERK and PDE4 cooperate to induce RAF isoform switching in melanomaNat Struct Mol Biol20111858459121478863
   PubMed Web of Science ®Google Scholar
• O’ByrnePMGauvreauGPhosphodiesterase-4-inhibition in COPDLancet200937466566719716944
   PubMed Web of Science ®Google Scholar
• NgkeloAAdcockIMNew treatments for COPDCurr Opin Pharmacol4182013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• CrosbyTFishRColesBMasonMDSystemic treatments for metastatic cutaneous melanomaCochrane Database Syst Rev20002CD00121510796759
   PubMedGoogle Scholar
• DemunterAStasMDegreefHDe Wolf-PeetersCvan den OordJJAnalysis of N- and K-ras mutations in the distinctive tumor progression phases of melanomaJ Invest Dermatol20011171483148911886512
   PubMed Web of Science ®Google Scholar
• EisenTAhmadTFlahertyKTSorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBr J Cancer20069558158616880785
   PubMed Web of Science ®Google Scholar
• McDermottDFSosmanJADouble-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupJ Clin Oncol2008262178218518445842
   PubMed Web of Science ®Google Scholar
• HauschildAAgarwalaSSTrefzerUResults of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaJ Clin Oncol2009272823283019349552
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med201036380981920818844
   PubMed Web of Science ®Google Scholar
• ChapmanPHauschildARobertCUpdated overall survival (OS) results for BRIM-3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanomaJ Clin Oncol201230Suppl Abstr 8502
   PubMed Web of Science ®Google Scholar
• SosmanJAKimKBSchuchterLSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibN Engl J Med201236670771422356324
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulationNature201046897397721107323
   PubMed Web of Science ®Google Scholar
• WagleNEmeryCBergerMFDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingJ Clin Oncol2011293085309621383288
   PubMed Web of Science ®Google Scholar
• KeffordRArkenauHBrownMPPhase I/II study of dabrafenib, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumorsJ Clin Oncol201028Suppl Abstr 8503
   Google Scholar
• KirkwoodJMLongGVTretzerUBREAK-MB: a Phase II study assessing overall intracranial response rate to dabrafenib (GSK2118436) in patient with BRAFV600E/K mutation-positive melanoma with brain metastasesJ Clin Oncol201230Suppl Abstr 8501
   Google Scholar
• DummerRRinderknechtJGoldingerSMAn open-label pilot study of vemurafenib in previously treated metastastic melanoma patients with brain metastasesJ Clin Oncol201129Suppl Abstr 8548
   Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet201238035836522735384
   PubMed Web of Science ®Google Scholar
• ChuEYWanatKAMillerCJDiverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic studyJ Am Acad Dermatol2012671265127222609219
   PubMed Web of Science ®Google Scholar
• SuFVirosAMilagreCRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsN Engl J Med201236620721522256804
   PubMed Web of Science ®Google Scholar
• ZimmerLHillenULivingstoneEAtypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionJ Clin Oncol2012302375238322614973
   PubMed Web of Science ®Google Scholar
• TrunzerKPavlickACSchuchterLPharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaJ Clin Oncol482013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• JohannessenCMBoehmJSKimSYCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature201046896897221107320
   PubMed Web of Science ®Google Scholar
• PrahalladASunCHuangSUnresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFRNature201248310010322281684
   PubMed Web of Science ®Google Scholar
• SethRCrookSIbrahemSConcomitant mutations and splice variants in KRAS and BRAF demonstrate complex peturbation of the Ras/Raf signaling pathway in advanced colorectal cancerGut2009581234124119474002
   PubMed Web of Science ®Google Scholar
• BaiteiEYZouMAl-MohannaFAberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinomaJ Pathol20092170771519156774
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med201236710711422663011
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med20123671694170323020132
   PubMed Web of Science ®Google Scholar
• CurtinJABusamKPinkelDSomatic activation of KIT in distinct subtypes of melanomaJ Clin Oncol2006244340434616908931
   PubMed Web of Science ®Google Scholar
• BeadlingCJacobson-DunlopEHodiFSKIT gene mutations and copy number in melanoma subtypesClin Cancer Res2008146821682818980976
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med200234747248012181401
   PubMed Web of Science ®Google Scholar
• CarvajalRDAntonescuCRWolchokJDKIT as a therapeutic target in metastatic melanomaJAMA20113052327233421642685
   PubMed Web of Science ®Google Scholar
• GuoJSiLKongYPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJ Clin Oncol2011292904290921690468
   PubMed Web of Science ®Google Scholar
• HodiFSFriedlanderPCorlessCLMajor response to imatinib mesylate in KIT-mutated melanomaJ Clin Oncol2008262046205118421059
   PubMed Web of Science ®Google Scholar
• SmalleyKSEisenTGFarnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cellsInt J Cancer200310516517512673674
   PubMed Web of Science ®Google Scholar
• NiessnerHBeckDSinnbergTThe farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cellsJ Invest Dermatol201113146847920944654
   PubMed Web of Science ®Google Scholar
• GajewskiTFSalamaAKSNiedzwieckiDPhase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)J Transl Med201212101024623228035
   PubMed Web of Science ®Google Scholar